Author:
Lewis O’Dene,Pastores Stephen M.
Publisher
Springer International Publishing
Reference69 articles.
1. Hematology/Oncology (Cancer) Approvals & Safety Notifications 2018 [updated 6-13-18]. Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm
2. Howard SC, Trifilio S, Gregory TK, Baxter N, McBride A. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol. 2016;95(4):563–73.
3. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.
4. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578–86.
5. Magrath IT, Semawere C, Nkwocha J. Causes of death in patients with Burkitt’s lymphoma – the role of supportive care in overall management. East Afr Med J. 1974;51(9):623–32.